Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Lymphoma, Ovarian Cancer, Bladder Cancer, Breast Cancer, Crohn's Disease (Regional Enteritis), Esophageal Cancer, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook